The integrated mechanistic model

This article is a mechanistic synthesis — not an experimental study — that proposes a unified explanatory model for how mucosal disease escalates across multiple body systems. The central hypothesis is that defective mucin glycosylation (either from genetic variants like FUT2 or from goblet-cell stress) produces mucus that is structurally inadequate, even when secreted in normal or high quantities. This poor-quality mucus allows bacteria to encroach on the epithelium, selects for mucolytic bacterial species, and progressively starves beneficial butyrate producers, creating a self-reinforcing downward spiral. The model traces downstream consequences through heparan sulfate degradation, bile acid signaling failure, unresolved inflammation, and HPA axis dysregulation. A specific anatomical prediction is made about the ileocecal junction as a site of physical accumulation and bacterial overgrowth due to the small intestine's thinner mucus layer. The framework is explicitly presented as a falsifiable hypothesis rather than a clinical protocol — its value lies in helping clinicians and researchers identify which dysfunctional subsystems are upstream drivers versus downstream consequences in a given patient. Its strength is integrative breadth; its limitation is that it remains untested as a whole system.

• The proposed primary lesion is defective mucin glycosylation — genetic (FUT2, glycosyltransferase variants) or acquired (ER stress in goblet cells) — producing mucus that is quantitatively normal but qualitatively inadequate as a barrier.
• A self-reinforcing pathological loop is described: defective mucus → mucolytic bacterial expansion (Ruminococcus gnavus, R. torques) → pro-inflammatory polysaccharide release + sialic acid liberation → loss of butyrate producers (Faecalibacterium, Roseburia) → further goblet-cell ER stress → more defective mucus, compounded by heparan sulfate/syndecan-1 degradation enabling protein leak and bacter
• The ileocecal junction is identified as a predicted anatomical bottleneck where sticky defective mucus, reduced Paneth cell α-defensin output, and possible ileocecal valve motor dysfunction converge to produce bacterial accumulation and physical obstruction.
• Secondary bile acid signaling failure (loss of FXR/TGR5 activation) and impaired lipid-mediator resolution (low omega-3 milieu) are incorporated as mechanisms that prevent the system from returning to homeostasis after each inflammatory episode.
• HPA axis dysregulation and vagal tone loss are proposed as systemic amplifiers that worsen each node of the loop, situating the model within a neuro-immune-mucosal framework rather than a purely gastrointestinal one.

This is a narrative mechanistic review and synthesis article with no original experimental data, animal models, or patient cohort. The authors integrate published findings across mucin biology, microbial ecology, epithelial barrier physiology, bile acid signaling, lipid mediator biology, and neuroendocrinology to construct a unified causal model. No statistical analyses, sample sizes, or follow-up periods apply. The output is a structured hypothesis with explicit falsifiability criteria rather than a clinical trial or observational study.

As a synthesis model with no primary data, none of the proposed causal links have been tested simultaneously in a single system; each node rests on evidence from separate studies, often in different disease contexts or animal models. The model cannot establish directionality or relative weighting among the proposed drivers — it is unknown, for example, whether FUT2 genetic variants are sufficient to initiate the cascade or whether they only matter in the presence of additional metabolic stressors. The next clarifying experiments would include: (1) prospective longitudinal multi-omic profiling (mucin glycan structure + microbiome + bile acids + barrier markers) in patients at known genetic risk before disease onset, and (2) germ-free or gnotobiotic animal colonization studies using mucin-glycosylation-deficient hosts to test whether mucolytic bacterial expansion is the necessary second hit. Clinical applicability requires decomposing the model into testable submodules and defining biomarker thresholds for each node.

This integrated mechanistic model functions as the capstone synthesis article within the mucosa topic corpus, explicitly extending the structural mucin-barrier descriptions found in earlier articles — it extends [§155] by providing an upstream glycosylation-defect explanation for why barrier-supportive interventions like Saccharomyces boulardii may produce variable results depending on the integrity of the underlying mucin scaffold. It parallels [§120], which demonstrates that microbial metabolite disruption (glutamine via GLS2/NF-κB in Eubacterium rectale) drives IBD pathology through overlapping immune and epithelial pathways, reinforcing the model's claim that loss of specific beneficial taxa has direct epithelial metabolic consequences. The model's prediction about ileocecal bacterial accumulation and the role of bile acid signaling failure is contextually supported by [§146], which shows that lithocholic acid-mediated macrophage reprogramming can attenuate ulcerative colitis, consistent with the model's FXR/TGR5 node. The self-reinforcing dysbiosis loop described here also parallels [§154], which addresses how fermentable substrate handling (FODMAP) modulates luminal bacterial behavior and symptom generation in functional gut disease, a population likely to overlap with patients at early stages of the cascade this model describes.

• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii's barrier-protective mechanisms operate at the epithelial junction level this model identifies as downstream of glycosylation failure — comparing the two clarifies which interventions address root cause versus consequence.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Eubacterium rectale's glutamine-metabolism pathway offers an experimentally tested single-taxon example of exactly the butyrate-producer loss node this model predicts, providing a concrete mechanistic anchor for one of the model's key claims.
• Intermittent fasting alleviates ulcerative colitis via lithocholic acid-mediated macrophage reprogramming
  Lithocholic acid and macrophage reprogramming in UC directly tests the secondary bile acid / FXR-TGR5 signaling arm of this model in a live disease context, making it an important empirical counterpart.
• Mechanism of FODMAP Restriction on FGID Patients
  The FODMAP-FGID mechanism article addresses luminal substrate-driven bacterial behavior changes, which maps onto the model's mucolytic bacterial expansion node and may help identify which dietary inputs accelerate or decelerate the proposed loop.
• Emapunil attenuates ulcerative colitis by suppressing Z-DNA binding protein 1 driven pyroptosis and pro-inflammatory polarization in macrophages
  Emapunil's suppression of ZBP1-driven pyroptosis in UC represents an orthogonal downstream pathway to the inflammation-resolution failure node in this model, useful for understanding whether the proposed loop converges on pyroptotic cell death as a terminal mechanism.